Group 1 - The company has launched OC-01, a nasal spray for increasing tear secretion in dry eye patients, marking a significant milestone in the treatment of dry eye syndrome in China [1] - OC-01 is the first and only nasal spray approved for treating dry eye symptoms globally, having received approval in the US in October 2021 and in mainland China in November 2024 [1] - The product is expected to provide a new treatment option for dry eye patients in China, enhancing the company's position in the ophthalmic market [1] Group 2 - The company focuses on ophthalmology as a key strategic development direction, emphasizing innovation in ophthalmic drugs and enhancing market competitiveness [2] - A comprehensive product system has been established, with multiple innovative products targeting conditions such as myopia, dry eye syndrome, and post-operative inflammation [2] - The company is committed to advancing innovative products and technologies, aiming to meet unmet clinical needs and expand its product pipeline through a global operational strategy [2]
远大医药(00512.HK)：治疗乾眼症的全球首创鼻喷产品OC-01正式获批后在中国大陆实现首批商业化处方落地